by Sydney Johnston | Nov 15, 2021 | ARPKD, Research
Published on November 16, 2021 | The PKD Foundation’s principal mission is to support basic, translational, and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD). This mission is...
by Sydney Johnston | Nov 2, 2021 | ADPKD, Research
Published on November 2, 2021 Feng Qian, Ph.D., University of Maryland School of Medicine How did you first get involved in PKD research? Feng: I first got involved in PKD research at my postdoctoral fellowship at Yale and then Johns Hopkins University. The...
by Sydney Johnston | Oct 19, 2021 | ADPKD, Research
Published on October 19, 2021 | As a genetic disease, ADPKD (autosomal dominant polycystic kidney disease) is caused by mutations in either the PKD1 or PKD2 gene. These genes encode the proteins polycystin-1 and polycystin-2, respectively, which together form the...
by Sydney Johnston | Jul 27, 2021 | Research
Published on July 27, 2021 Eduardo Chini, M.D., Ph.D., Mayo Clinic How did you first get involved in PKD research? Eduardo: I’ve trained with Dr. Thomas Dousa one of the found fathers of biochemical nephrology. He studied signal transduction in kidney disease...
by Sydney Johnston | Jun 29, 2021 | Research
Published on June 29, 2021 | On June 1, the STAGED-PKD study was halted due to an inability to meet futility criteria. The study was looking at an investigational drug called venglustat to treat ADPKD. Over 500 patients signed up to participate. What does it mean to...
by Sydney Johnston | Jun 22, 2021 | Research
Published on June 22, 2021 Xiangqin Cui, Ph.D., Emory University How did you first get involved in PKD research? Xiangqin: When I was a postdoc in Dr. Gary Churchill’s lab at the Jackson Laboratory, Dr. Churchill had collaborations with Dr. Lisa Guay-Woodford...
